ArticleClinicoEconomics and outcomes research : CEOR2017

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy.

Valentina Lorenzoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.